Abstract 239P
Background
The treatment of locally advanced cervical cancer with definitive chemoradiation (CRT) is associated with vaginal toxicity and altered sexual satisfaction. This prospective study compared patient-reported sexual adjustment, vaginal dosimetry, and physician-reported vaginal toxicity in patients with cervical cancer treated with CRT and brachytherapy (BT) following counselling for vaginal dilatation or resuming sexual activities with those who did not comply.
Methods
Between 2016 and 2018, histopathologically proven and staged IB-IVA patients with cervical cancer receiving definitive CRT were enrolled in a feasibility study assessing the impact of compliance and its outcome in terms of sexual adjustment. Patients completed the validated sexual adjustment questionnaire (SAQ) and EORTC CX24 before BT (baseline) and during follow-up. Physician-reported vaginal toxicity was recorded. Dosimetric analysis was done with focus on rectovaginal point, mean vaginal dose, and D2cm3.A multivariable linear mixed-effects model was used to examine the association between total and individual scores (repeated measures) and covariates.
Results
A total of 75 patients complied with the counselling in terms of either resuming sexual activities or using vaginal dilators as compared to 65 patients who did not use any intervention in spite of the counselling. The diagnosis of cervical cancer and treatment negatively impacted sexual relationships in 66% and 68%, respectively. However, counselling and intervention helped improve the sexual adjustment over time (p = 0.023). There were no associations between sexual adjustment and the ICRU defined Measurements of rectovaginal point dose or clinical vaginal involvement. Stage (p < 0.001), age (p = 0.012) and diabetes (p = 0.037) were found to have an important association with delayed adjustments post intervention.
Conclusions
Vaginal stenosis is an important late toxicity associated with radiation therapy and in India, counselling patients for resuming sexual relations can be a taboo. However, our study indicates good compliance among patients for use of intervention to prevent such complications and improved outcomes have been seen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract